Patent details

Basic Information

Publication number:

91534

Type:

SPC

SPC Type:

Medical

Basic Patent Number:

EP037007408

Legal Status:

Lapsed

Application number:

91534

First applicant's nationality:

Procedural language:

French

Marketing Authorization

Marketing Authorization Number:

EU/1/08/459/001 - Tredaptive,Trevaclyn et Pelzont

Marketing Authorization Type:

Marketing Authorization Date:

07/07/2008

Marketing Authorization Status:

Accepted

Marketing Authorization Country:

Dates

Filing date:

27/02/2009

First Marketing Authorization date:

07/07/2008

Grant date:

27/04/2009

Activation date:

Publication date:

27/04/2009

Lapsed date:

22/01/2023

Expiration date:

Renunciation date:

Revocation date:

Annulment date:

Basic SPC Expiration:

07/07/2023

SPC Extension Expiration:

07/07/2023

Rejection date:

Withdrawal date:

Owner

From:

27/02/2009

 

 

Name:

Merck Frosst Canada Ltd.

Address:

16711 Trans-Canada Highway, Kirkland, Québec H9H 3L1, Canada (CA)

Agent

Name:

KIRKPATRICK

From:

27/02/2009

Address:

AVENUE WOLFERS 32, 1310, LA HULPE, Belgium (BE)

To:

Inventor

1

Name:

STURINO Claudio

Address:

Canada (CA)

2

Name:

WANG Zhaoyin

Address:

Canada (CA)

3

Name:

LACHANCE Nicolas

Address:

Canada (CA)

4

Name:

LI Lianhai

Address:

Canada (CA)

5

Name:

BERTHELETTE Carl

Address:

Canada (CA)

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages